Palliative care decreases life-ending among cancer patients despite access to euthanasia

This article originally appeared here.
Share this content:
Belgium Study Tracks Trends in End-of-Life Decision Making
Belgium Study Tracks Trends in End-of-Life Decision Making

(HealthDay News) -- In Belgium, between 1998 and 2007, euthanasia was legalized and palliative care was intensified, which led to an increase in end-of-life decisions (ELDs) and fewer life-ending acts without the patient's explicit request, according to research published online March 11 in the Journal of Clinical Oncology.

Koen Pardon, Ph.D., of Ghent University and Vrije Universiteit in Brussels, and colleagues surveyed physicians who had signed 6,927 select death certificates in 2007 to evaluate ELD trends in patients with and without cancer and compare those results to a similar study completed in 1998, before euthanasia was legalized.

From 1998 to 2007, ELDs increased by 6.7% for cancer patients and 14.9% for patients without cancer, primarily due to an increase in intensified symptom alleviation (53.8% and 31.7% for cancer and non-cancer patients). Euthanasia was also more commonly practiced in cancer versus non-cancer patients (6.8% versus 0.9%). Overall, 69.7% of cancer patients and 83.5% of patients without cancer were involved in making ELDs.

"To conclude, the higher ELD incidence in patients with cancer compared with those without is probably related to differences in disease trajectories and access to end-of-life care," the authors write. "Between 1998 and 2007, during which time euthanasia was legalized and palliative care intensified, overall ELDs increased, including those caused by acts of symptom alleviation and euthanasia, with a decrease in life-ending without explicit request."

Full Text (subscription or payment may be required)

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs